Free tool
FAERS Monitor: Elzonris
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761116 or its brand name (Elzonris, Tagraxofusp-Erzs). Reports on generic versions are filed under their own applications.
Reports
538
Serious
459
85% of reports
Hospitalization
135
Death reported
161
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- capillary leak syndrome130
- pyrexia47
- off label use43
- death41
- disease progression38
- thrombocytopenia35
- blood albumin decreased29
- drug ineffective28
- weight increased28
- tumour lysis syndrome27
- hypoalbuminaemia25
- acute kidney injury24
- sepsis23
- hypotension22
- transaminases increased22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 58 |
| 2020 | 60 |
| 2021 | 75 |
| 2022 | 72 |
| 2023 | 87 |
| 2024 | 69 |
| 2025 | 63 |
| 2026 | 54 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,621 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| capillary leak syndromeSignal | 130 | 2623.7 | 2244.3 | 316,981 |
| blood albumin decreasedSignal | 29 | 143.4 | 100.6 | 3,948 |
| hypoalbuminaemiaSignal | 25 | 126.2 | 86.0 | 2,972 |
| tumour lysis syndromeSignal | 27 | 120.3 | 83.3 | 3,069 |
| transaminases increasedSignal | 22 | 38.7 | 25.7 | 771 |
| disease progressionSignal | 38 | 12.6 | 9.2 | 395 |
| thrombocytopeniaSignal | 35 | 12.2 | 8.9 | 352 |
| sepsisSignal | 23 | 8.1 | 5.4 | 136 |
| acute kidney injurySignal | 24 | 6.1 | 4.1 | 99 |
| pyrexiaSignal | 47 | 5.3 | 4.0 | 163 |
| weight increasedSignal | 28 | 4.9 | 3.4 | 84 |
| hypotensionSignal | 22 | 4.3 | 2.8 | 53 |
| off label use | 43 | 1.9 | 1.4 | 19 |
| death | 41 | 1.9 | 1.4 | 16 |
| drug ineffective | 28 | 0.8 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.